title: Acquired angioedema: a new target for rituximab?
authors.forename: Panayiotis D
authors.initials: PD
authors.lastname: Ziakas
authors.forename: Stavroula
authors.initials: S
authors.lastname: Giannouli
authors.forename: Erasmia
authors.initials: E
authors.lastname: Psimenou
authors.forename: Kompoti
authors.initials: K
authors.lastname: Evangelia
authors.forename: Athanasios G
authors.initials: AG
authors.lastname: Tzioufas
authors.forename: Michalis
authors.initials: M
authors.lastname: Voulgarelis
mesh_terms: D000799:Angioedema / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D003167:Complement Activation; D003172:Complement C1 / Q000172:deficiency; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D003172:Complement C1; D007155:Immunologic Factors; D000069283:Rituximab